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In the beginning, there was 1 deﬁnition of bleeding com-
plications. The TIMI (Thrombolysis In Myocardial Infarc-
tion) deﬁnition of bleeding was designed to analyze the safety
of 2 different thrombolytic regimens in the context of a
landmark ST-segment elevation myocardial infarction
(STEMI) reperfusion trial (1). The TIMI deﬁnition is
simple: major and minor bleeding classes are deﬁned ac-
cording to hemoglobin decrease or the presence of intracra-
nial bleeding. As studies of acute myocardial infarction
progressed, trial-speciﬁc deﬁnitions for bleeding added
nuance in measurement (e.g., transfusion requirements, he-
modynamic instability, organ-speciﬁc bleeding) and incon-
sistency in language (e.g., major, minor, moderate, severe,
mild, nuisance). Bleeding discussions became a source of
endless controversy: 9 different deﬁnitions of bleeding were
used in 13 trials of antithrombotic therapy, with signiﬁcant
implications for interpretations of drug safety (2).See page 1866In 2008, the ABC (Academic Bleeding Consensus)
Multidisciplinary Group convened “with the goal of
developing a consensus approach to measure the incidence
and severity of hemorrhagic complications” (3). This group
developed a uniform framework for collecting data but
decided against returning to the halcyon days of a single
deﬁnition of bleeding. The framework strategy is
noncontroversial: all trials should collect the same data.
This fully deconstructed bleeding approach encouraged
trial researchers to customize signiﬁcant bleeding according
to the clinical syndrome being studied: “As an alternative to
using a single standard bleeding deﬁnition, the consensus
group recommended standardized collection and reporting
of bleeding-related data elements that describe the timing
and site of bleeding, the direct consequences of bleeding
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leading to death).”
Two years later, BARC (Bleeding Academic Research
Consortium) convened; their goal was to “.to develop,
disseminate and ultimately adopt standardized bleeding end
point deﬁnitions for patients receiving antithrombotic
therapy” (4). The BARC group gave us a partially decon-
structed deﬁnition of bleeding: qualitative terms such as
major and minor were discarded and replaced with a 5-tiered
system (Fig. 1). As stated in a commentary by the U.S. Food
and Drug Administration: “The FDA supports the use of
standardized endpoint deﬁnitions that have been validated
and properly reﬂect clinical outcomes” (5). In this issue of
the Journal, Kikkert et al. (6), from the University of
Amsterdam, provide us with insight into the BARC
bleeding deﬁnitions as they relate to the clinical outcome of
1-year mortality after percutaneous coronary intervention
(PCI) for STEMI.
Toward a uniﬁed deﬁnition of bleeding. The analysis by
Kikkert et al. (6) is the second study to validate the BARC
bleeding deﬁnition, and it focused on patients undergoing
PCI for STEMI. A previous study by Ndrepepa et al. (7)
used a validation set consisting of 6 of the ISAR (Intra-
coronary Stenting and Antithrombotic Regimen) clinical
trials focused on patients undergoing lower risk PCI. Both
studies validate the risk of PCI-related BARC bleeding on
1-year mortality. These 2 important studies are both
disparate and complimentary (Table 1). For example, the
study by Ndrepepa et al. (7) addressed BARC bleeding
prognosis in a clinical trial population that was largely stable
and relatively lower risk; the Kikkert et al. (6) study focuses
on a registry group with STEMI only. Thus, it is not sur-
prising that the 2 studies do not agree on even the most basic
question: how often does BARC bleeding occur? The 3-fold
variation in the incidence of BARC type 2 and 3 bleeding is
likely due to differences in patient populations. However,
one cannot exclude the possibility that retrospectively
assessing the elements of BARC bleeding may be chal-
lenging and that variations may be due to errors of retro-
spection. The retrospective application of BARC bleeding
classiﬁcations seems to be especially challenging at the ex-
tremes: the Kikkert et al. (6) analysis chose to exclude the
BARC type 1 bleeding class, recognizing the difﬁculty of
retrospectively assessing “bleeding that is not actionable.”
The analysis by Ndrepepa et al. (7) chose to exclude BARC
type 5 bleeding and reassign each of these bleeds to a lower
tier to avoid the circular reasoning of determining the impact
of fatal bleeds on 1-year mortality.
There is a more glaring concern: the prognostic value of
BARC bleeding classes is not necessarily consistent. The
authors of both groups used multivariable Cox proportional
hazards models to assess independent correlates of 1-year
mortality, including BARC bleeding. The ISAR group found
BARC type 2 or 3 bleeding events had an independent
2- to 3-fold increased hazard of 1-year death (7). The study by
Kikkert et al. (6) used similar multivariable regression analysis
Figure 1
BARC Bleeding: From Uniﬁed Trial Deﬁnitions to
Uniﬁed Clinical Decision Making
BARC (Bleeding Academic Research Consortium) is a partially deconstructed
bleeding deﬁnition with up to 7 different classes of bleeding. A simpliﬁcation into
major and minor bleeding groups may provide clinical guidelines as well as speciﬁc
validation endpoints. CABG ¼ coronary artery bypass graft.
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1877but reached an entirely different conclusion: BARC type 2
and 3a bleeding did not increase the adjusted hazard ratio
for 1-year mortality, and only the sum of BARC type 3bþ 3c
bleeding increased the mortality risk. Comparing these
discordant outcomes is difﬁcult because the analyses used
BARC bleeding either inclusively (BARC type 2) or ordi-
nately (equal to BARC type 2). We are left with 2 potentially
disturbing conclusions: BARC bleeding reﬂects clinical out-
comes only in selected patient populations or variations in
statistical analyses make comparisons across studies once again
challenging. Either way, the uniﬁed demonstration of BARC
clinical relevance is unclear based on the 1-year mortality
analyses of these 2 groups.
The TIMI deﬁnition of bleeding is far from perfect.
Thus, it is worthwhile that the investigators compare the
relative value of multiple bleeding scales in predicting 1-year
mortality. In the analysis by Ndrepepa et al. (7), 3 bleeding
scales provide independent predictive value with respect toTable 1 Validation of the BARC Bleeding Deﬁnitions According to 1-
ISAR: Ndrepepa et al. (7)
(N ¼ 12,459)
Timing of bleeding episode Index hospitalization for PCI Index
Patient population 6 Pooled clinical trials Single
Clinical spectrum PCI for angina, UA, and NSTEMI PCI fo
Incidence of BARC type 2 1.4% 4.4%
Incidence of BARC type 3 3.9% 14.2%
Incidence of BARC type 3c 0.08% 0.04%
BARC type 2: risk of 1-year death HR ¼ 2.72* HR ¼
BARC type 3: risk of 1-year death HR ¼ 3.19* Type 3
Type 3
*Adjusted hazard ratio (HR) using Cox model for BARC (Bleeding Academic Research Consortium) type
ISAR ¼ Intracoronary Stenting and Antithrombotic Regimen; NSTEMI ¼ non–ST-segment elevation my1-year mortality: REPLACE (Randomized Evaluation in
PCI Linking Angiomax to Reduced Clinical Events) 2
major bleeding, 3.1-fold increased risk; TIMI major þ
minor bleeding, 3.6-fold increased risk; and BARC type 2
bleeding, 2.7-fold increased risk. The analysis by Kikkert
et al. (6) uses TIMI, ISTH (International Society on
Thrombosis and Haemostasis), and GUSTO (Global Use of
Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries) as comparators to BARC.
Patients having a TIMI major bleed have a 2-fold increased
hazard of 1-year death; patients having a BARC type 3b þ
3c bleed have a 1.84-fold increased hazard of 1-year death.
Once again, we are left with an unclear comparison between
the 2 studies, but what is clear is the apparent lack of su-
periority of the new bleeding scale. Thus, BARC can neither
provide uniform predictive value nor demonstrate clear su-
periority compared with previous deﬁnitions.
Bleeding for clinicians. In light of these grey areas in
applying the BARC bleeding deﬁnitions, the original pur-
pose of the BARC and ABC consensus groups should be
reconsidered. All bleeding scales have been created for fed-
eral agencies, industry, academia, and clinical trials. How-
ever, times have changed: the connection between bleeding
events and morbidity/mortality is no longer emphasized only
in labeling decisions by the U.S. Food and Drug Adminis-
tration. According to the 2011 American College of Car-
diology/American Heart Association Guidelines for PCI,
bleeding assessment is part of our routine clinical practice:
All patients should be evaluated for risk of bleeding before
PCI (Class I, Level of Evidence: C) (8). To allow cardiol-
ogists to meet the guideline recommendation, we need a
uniﬁed deﬁnition for bleeding that is clinically meaningful
and easy to use.
The BARC consensus group is to be congratulated for
bringing forth a new classiﬁcation of bleeding that could
provide uniformity for clinical trials. This classiﬁcation is
potentially superior to any other deﬁnition of bleeding: it
includes clinically and laboratory-measured bleeding, has
organ-speciﬁc nuance, and includes post-bypass surgery
bleeding parameters. BARC importantly highlights the
need to collect data on softer bleeding endpoints (BARCYear Mortality
Amsterdam: Kikkert et al. (6)
(N ¼ 2,002)
Summary
(N ¼ 14,461)
hospitalization for PCI Uniform time interval analysis
-center registry Different patient populations
r STEMI, including cardiogenic shock Different clinical spectrums
More than 3-fold variation in incidence
More than 3-fold variation in incidence
Cranial/ocular bleeds are very rare
0.96y Potentially discordant
a: HR ¼ 0.97y
b þ 3c: HR ¼ 1.84y
Potentially discordant
2 or 3 bleeding. yAdjusted HR using Cox model for BARC type 2 and BARC type 3 bleeding.
ocardial infarction; PCI ¼ percutaneous coronary intervention; UA ¼ unstable angina.
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1878type 1): such previously understudied bleeding events may
not predict mortality but will affect the patient’s quality of
life (9,10). In deconstructing the language of bleeding to its
element parts or to a hierarchical tier, something has been
gained: uniformity. However, something vital has also been
lost: words like major, minor, moderate, and severe are
confusing in their inconsistency but critical in their
connection to actual decision making. The 5 tiers and 3
subclasses of BARC bleeding are a memory challenge that
most of us will fail. Can a practicing cardiologist be expected
to choose a treatment strategy weighing the risk of stent
thrombosis against a hazard of BARC type 3b þ 3c
bleeding? Conversely, weighing a 50% decrease in stent
thrombosis compared with a doubling of minor bleeding is a
clinical language that resonates.
Validation and memory. The difﬁculty in ﬁnding clear
proof of BARC’s superiority provides a chance to revisit the
deﬁnition to ﬁnd a simpler scale that brings back descriptive
terms that provide relative meaning (Fig. 1). From 7
different classes of bleeding, we need to ﬁnd intrinsic
meaning and less memorization by rediscovering words like
major and minor. Second, we need to remove fatal bleeding
as a class; fatal bleeding clearly ﬁts the clinical meaning of
the term “major.” Third, we need to address a concern of the
regulatory agencies: what is the reason to classify coronary
artery bypass graft–related bleeding as prognostically
different from PCI-related bleeds (5)? One deﬁnition could
apply to all pharmacological studies, clinical syndromes, and
invasive cardiac procedures. Fourth, we need to embrace the
softer deﬁnitions created by BARC (9): there are now 2
groups that have validated the BARC bleeding scale with
respect to a single endpoint (1-year mortality) (6,7). How-
ever, nonfatal bleeding complications are of signiﬁcant in-
terest to clinicians and patients; prolonged hospitalization,
increased hospital costs, and diminished quality of life
matter (11). Thus, we should set goals for a clinical bleeding
scale accordingly. For minor bleeding, the scale must predict
events that are nonfatal; for major bleeding events, the scale
must predict 1-year mortality.
As we reconstruct the language of bleeding, we need to
meet the needs of those having the conversation; that
group is no longer simply trialists and federal agencies. The
bleeding conversation now includes all of us who are taking
care of cardiology patients. A uniﬁed, translatable bleeding
scale that validates minor and major concerns across the
spectrum of both bleeding events and cardiovascularclinical trials is worthy of further effort: after the ABC,
BARC, ISAR, and Amsterdam analyses, we are getting
closer.
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